The company’s co-founders said they are leaving to start a new mRNA-based company.

The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their ...

Uğur Şahin and Özlem Türeci, a Turkish husband-and-wife team, became unlikely celebrities during the pandemic for their world ...

The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...

BERLIN, Jan 1 (Reuters) - BioNTech (22UAy.DE), opens new tab is working flat out with partner Pfizer (PFE.N), opens new tab to boost production of their COVID-19 vaccine, its founders said, warning ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...

PHILADELPHIA -- Pfizer and BioNTech said Tuesday they have submitted Covid-19 vaccine data on children ages 5 to 11 to the US Food and Drug Administration for initial review, but are not yet seeking ...

By Ludwig Burger and Patricia Weiss FRANKFURT, March 10 (Reuters) - BioNTech's two co-founders and leading executives will leave the COVID-19 vaccine maker by the end of the year to start a new ...

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

Q4 2025 earnings call: 2026 revenue guidance, COVID vaccine outlook, oncology pipeline updates, and leadership transition—read now.